Adaptive Biotechnologies Corp (ADPT) is a biotechnology company that was founded in 2009 and is headquartered in Seattle, Washington. The company specializes in immune system profiling through the use of proprietary technologies. The goal of the company is to improve patient care by developing novel diagnostics and therapeutics that leverage the immune system to fight disease.
The company's proprietary immune profiling platform, called ImmunoSEQ, allows for the analysis of millions of immune cells at once and has been used in numerous research studies and clinical trials. This technology can help identify the genetic signatures of immune cells and provide insights into how the immune system responds to various diseases.
Adaptive Biotechnologies Corp has a number of partnerships with leading pharmaceutical and biotechnology companies, which allows it to apply its technologies to a wide range of diseases and conditions. For example, the company has partnered with Genentech to develop personalized cancer therapies, and with Microsoft to develop machine learning tools for analyzing immune system data.
As of February 18, 2023, Adaptive Biotechnologies Corp was listed on the NASDAQ stock exchange under the symbol ADPT, with a market capitalization of approximately $10 billion. With its innovative technologies and partnerships with leading companies, the company is well-positioned to continue making significant contributions to the field of biotechnology and healthcare.
|
